RxDoctor Payments DataLook up a doctor →

Steven Grekin, DO

Dermatology · Warren, MINPI 1407836877

Payments from drug & device makers

$200,089in general payments, 2019–2025

Across 1,007 payments — averaging $198.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$41K
  • Amgen$24K
  • Journey Medical Corporation$20K
  • Avita Medical Americas, LLC$19K
  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • Almirall LLC$12K
  • plus $68K from 44 others

What the payments were for

  • Consulting fees$5,61512%
  • Speaking & faculty fees$24,95052%
  • Travel & lodging$1220%
  • Food & beverage$16,91935%
  • Education$6731%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$200,089 in reported general payments places this provider in the 90th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$254,794
Medicare patients
1,004
Services billed
5,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab22$297,044
Skyrizi PenRisankizumab-Rzaa14$296,367
OtezlaApremilast54$260,827
Dupixent SyringeDupilumab61$227,710
Taltz AutoinjectorIxekizumab21$163,972
Dupixent PenDupilumab44$163,837
RinvoqUpadacitinib22$134,335
SotyktuDeucravacitinib15$94,521
Humira(Cf) PenAdalimumab13$86,697
Gentamicin Sulfate156$6,169
Ketoconazole341$6,042
Fluticasone Propionate282$5,782
Tacrolimus49$4,348
Mometasone Furoate177$3,241
Ammonium Lactate201$3,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,563$297,04422 claims
AmgenOtezla$24,419$260,82754 claims
AbbVieRinvoq$2,495$134,33522 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$608$94,52115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 dermatology providers in Michigan.

Other dermatology in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →